LTRN
Lantern Pharma Inc. (LTRN) SWOT Analysis Analysis (2026)
Strengths
Liquidity appears adequate with a current and quick ratio near 2.0, which compares favorably with more levered small-cap peers that often operate with tighter working-capital buffers.
Net debt to EBITDA is modest at 0.36x, limiting balance-sheet pressure versus peers that rely more heavily on debt financing to fund operations and growth.
Cash conversion cycle is reported at zero, suggesting working-capital efficiency that can support liquidity relative to peers with longer inventory and receivables cycles.
Weaknesses
Return on invested capital is negative at -3.6%, indicating capital is not yet generating economic returns and lagging profitable peers with positive reinvestment spreads.
The absence of reported operating and gross margins points to limited visible earnings quality, which weakens comparability against peers with established margin structures.
Debt-to-equity is effectively not meaningful at a negative reading, reflecting a capital structure that is difficult to benchmark and typically associated with weaker equity positioning than peers.
Opportunities
If management converts current liquidity into sustained operating scale, the company could narrow the gap versus peers that already monetize working capital into positive returns.
A low leverage profile leaves room to fund commercialization or restructuring more flexibly than peers with constrained borrowing capacity, improving optionality over time.
Any improvement in asset utilization would have an outsized effect because the current negative ROIC leaves substantial room to close the performance gap versus peers.
Threats
Persistent negative ROIC threatens long-term competitiveness because peers with positive capital returns can reinvest faster and compound market share more effectively.
Without demonstrated margin data, the company remains exposed to peers with clearer cost advantages, which can pressure pricing power and investor confidence.
If operating performance does not improve, even moderate leverage can become less supportive than peers with stronger cash generation and more resilient earnings.
Overall Score
LTRN’s structural positioning versus peers is weak overall because negative capital returns outweigh its relatively solid liquidity and modest leverage.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Lantern Pharma Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

